ReviewiScience2026
Tumor infiltrating B cells and tertiary lymphoid structures in pancreatic cancer prognosis and therapy.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by a profoundly immunosuppressive tumor microenvironment (TME) that limits response to immunotherapy. Tumor-infiltrating B cells (TIBs) constitute a key TME component, and in certain patient subsets, they collaborate with T cells, dendritic cells, and other immune cells to form tertiary lymphoid structures (TLSs). Current evidence reveals functionally distinct TIB subsets in PDAC; while some subsets promote tumor progression, others enhance anti-tumor immunity. Therefore, comprehensively elucidating these dualistic roles is imperative. Concurrently, the presence of mature TLSs within PDAC correlates with improved prognosis and therapeutic outcomes. Understanding TIB and TLS dynamics, along with their interactions with other TME components, may unveil novel strategies to overcome immune suppression in PDAC. This review synthesizes recent advances in TIB and TLS research, evaluates their prognostic significance, and explores potential clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.